A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
Saved in:
| Title: | A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. |
|---|---|
| Authors: | Rustin, G.1, Vergote, I.2, Micha, J.P.3, Duska, L.R.4, Reed, N.5, Bendell, J.6, Spitz, D.7, Dark, G.8, Hoch, U.9, Tagliaferri, M.9, Hannah, A.L.9, Garcia, A.A.10,11 agarc6@lsuhsc.edu |
| Source: | Gynecologic Oncology. Nov2017, Vol. 147 Issue 2, p276-282. 7p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
